Quick Answer
Xenetic Biosciences, Inc. reported Diluted EPS of $1.58 per share (loss) for fiscal year 2025.
Xenetic Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.58 | +38.5% |
| 2024 | -$2.57 | +5.2% |
| 2023 | -$2.71 | +41.2% |
| 2022 | -$4.61 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.33 | -17.9% | +26.7% |
| June 30, 2025 | -$0.45 | +45.8% | +23.7% |
| March 31, 2025 | -$0.59 | +24.4% | -110.7% |
| September 30, 2024 | -$0.28 | +59.4% | +66.3% |
| June 30, 2024 | -$0.83 | -20.3% | -6.4% |
| March 31, 2024 | -$0.78 | -39.3% | -13.0% |
| September 30, 2023 | -$0.69 | -23.2% | +0.0% |
| June 30, 2023 | -$0.69 | +63.7% | -23.2% |
- Xenetic Biosciences, Inc. showed an increase of +38.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Xenetic Biosciences, Inc.’s diluted eps has grown by 65.7% (from $4.61 per share (loss) to $1.58 per share (loss)).
- The most recent figure is from Xenetic Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: